Venture Corp. Ltd.

FeelBetter, a machine learning-enabled medication-management platform focused on polypharmacy, announced it secured $5.9 million in funding led by Firstime Ventures and Shoni Health Ventures. Random Forest VC, The Group Ventures, and existing FeelBetter investor Triventures also participated in the round. The latest round brings the company's total raise to $8 million. WHAT IT DOES FeelBetter focuses on the polypharmacy paradigm, the simultaneous use of multiple drugs by one patient for one or more conditions. The company's AI-enabled platform analyzes data on a patient's health status and medical history, pharmacology and clinical guidelines to examine the connections between the different sources to improve a patient's medication regimen. The company will use the funds to expand its reach and advance its platform. "At a time when investors are especially selective about the types of bets they are taking, this round and vote of confidence from the world-class teams at Firstime Ventures, Shoni Health Ventures, Random Forest VC, Triventures, and The Venture Group, as well as angel investors, validates the need for and potential of our pharmaco-clinical intelligence as a solution for the growing, global health challenge posed by suboptimal medication management," Liat Primor, FeelBetter's CEO and cofounder said in a statement. MARKET SNAPSHOT Polypharmacy has been shown to affect one's health-related quality of life negatively, is often seen in older adults and results in a large number of hospital admissions. Other companies in the medication management space include Arine, which offers data analytics tools for medication management, and retail giant Walmart, which purchased digital medication management company CareZone's tech platform, patents and intellectual property in 2020.

First-of-Its-Kind Solution Helps Ensure Medicines Prescribed to Patients are Safe, Effective, and Appropriate, Tackling Growing Public Health Challenge Posed by Suboptimal Medication Use FeelBetter's Pharmaco-Clinical Intelligence Aids in Proactively Identifying and Managing Polypharmacy-Related Risks, Reducing Preventable Deterioration and Hospitalizations BOSTON and TEL AVIV, Israel , July 31, 2023 /PRNewswire/ -- FeelBetter, the leading provider of medication management technology and pioneer of Pharmaco-Clinical Intelligence, today announced that it has raised $5.9 million in funding. Firstime Ventures and Shoni Health Ventures led the funding round with participation from Random Forest VC, The Group Ventures, and existing FeelBetter investor Triventures, bringing the Company's total funding to $8 million. A growing public health concern for senior patients, many of whom have multiple chronic conditions, the simultaneous use of multiple medications paves the way for poor health outcomes, increased use of health services, and rising care costs. In the US alone, every year, suboptimal medication management results in 275,000 deaths and more than $528B in avoidable costs. Launched in 2018, FeelBetter is tackling the challenges associated with suboptimal medication management among polypharmacy patients. Led by an interdisciplinary team of clinicians, clinical pharmacists, and technologists, FeelBetter has pioneered a new category of technology called Pharmaco-Clinical Intelligence. It combines novel pharmacology and clinical capabilities and is changing the polypharmacy paradigm on both an individual and population health level. A comprehensive solution powered by AI and machine learning capabilities, FeelBetter's Pharmaco-Clinical Intelligence drives proactive, personalized medication management, helping healthcare professionals ensure that their patients' medication regimens are safe, effective, and appropriate. "FeelBetter's purpose-built technology makes it possible to deliver a more personalized, whole-patient approach to medication management – one that goes beyond a single illness, diagnosis, or point in time, and comprehensively focuses on each individual's care journey," said Liat Primor, FeelBetter's CEO and Co-Founder. "At a time when investors are especially selective about the types of bets they are taking, this round and vote of confidence from the world-class teams at Fristime Ventures, Shoni Health Ventures, Random Forest VC, Triventures, and The Venture Group, as well as angel investors, validates the need for and potential of our Pharmaco-Clinical Intelligence as a solution for the growing, global health challenge posed by suboptimal medication management." Yoram Hordan, FeelBetter's CTO, COO, and Co-Founder, added: "The funding will enable us to expand our reach, further refine our solution, and empower more healthcare providers to deliver personalized, proactive care. Our Pharmaco-Clinical Intelligence, developed collaboratively by clinical and pharmacology experts alongside technology and machine learning specialists, seamlessly matches a patient's specific clinical and pharmacology data with their sequence of health events. This unlocks unparalleled accuracy in detecting at-risk patients both individually and population wide and enables new levels of precision in disease management and prevention." Recognizing that a range of diverse factors can influence a senior patient's health status, FeelBetter's Pharmaco-Clinical Intelligence synthesizes and analyzes healthcare data from multiple sources to pinpoint patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management. The SaaS solution also proactively suggests immediate and actionable interventions to reduce polypharmacy risks, and aids healthcare providers in monitoring patients' progress and measuring the impact of clinical interventions. Additionally, by using FeelBetter, provider organizations can more effectively and efficiently allocate resources to better serve patients, and minimize preventable, costly use of healthcare services. "FeelBetter's algorithm has been trained on two decades of longitudinal clinical, pharmacy, claims, and lab data from hundreds of thousands of patients to find patterns in the complex connections and relationships between disparate data sources," said Michael Kerbis, Founding Partner, Random Forest VC. "When taken together, these patterns can capture the full picture of a patient's health journey, enabling FeelBetter to predict which individuals are at the greatest risk of adverse events related to suboptimal medication regimens and recommend timely clinical interventions to drive better health outcomes." Eran Lerer, CEO and Managing Partner, Shoni Health Ventures, said: "From risk stratifying patients to preventing adverse events so patients can safely stay in their communities, FeelBetter offers a proven, end-to-end solution for the suboptimal medication management problem. It's a groundbreaking tool that is poised to change how the medical community approaches polypharmacy, and we're thrilled to take part in this important transformation." Keren Kopilov, Partner, Firstime Ventures, added: "By incorporating the expertise of physicians and clinical pharmacists, as well as leveraging data from all relevant sources, FeelBetter provides a solution that is uniquely comprehensive. It intuitively fits into clinical workflows and enables optimized medication management at unparalleled speed and scale. We look forward to leveraging our expertise to support FeelBetter's mission and continued growth as it meets the tremendous opportunities ahead." About FeelBetter FeelBetter is the pioneer of Pharmaco-Clinical Intelligence, changing the polypharmacy paradigm on both an individual and population health level with a comprehensive solution designed to tackle the challenges associated with suboptimal medication management. Powered by AI and machine learning capabilities, FeelBetter's Pharmaco-Clinical Intelligence drives personalized medication management, helping healthcare professionals ensure that their patients' medication regimens are safe, effective, and appropriate. The technology pinpoints patients at high risk of deterioration and preventable hospitalization due to suboptimal medication management, and proactively suggests immediate and actionable interventions to reduce these risks. Provider organizations use FeelBetter to monitor their patients' progress and more proactively deliver the right follow-up care, as well as to efficiently allocate resources and minimize preventable, costly use of healthcare services. Led by an interdisciplinary team of clinicians, clinical pharmacists, and technologists, FeelBetter is headquartered in Boston and Tel Aviv, Israel. Investors include Firstime Ventures, Shoni Health Ventures, Triventures, Random Forest VC, The Group Ventures, and GoodCompany Ventures. To learn more, visit feelbetter.healthcare. Media Contact Nicole Pariser [email protected]com SOURCE FeelBetter

DUBLIN--( BUSINESS WIRE )--The "Sleep Disorder Treatment Drugs Markets in China" report has been added to ResearchAndMarkets.com's offering. China's demand for Sleep Disorder Treatment Drugs has grown at a fast pace in the past decade. In the next decade, both production and demand will continue to grow. The Chinese economy maintains a high speed growth which has been stimulated by the consecutive increases of industrial output, import & export, consumer consumption and capital investment for over two decades. This new study examines China's economic trends, investment environment, industry development, supply and demand, industry capacity, industry structure, marketing channels and major industry participants. Historical data (2012, 2017 and 2022) and long-term forecasts through 2027 and 2032 are presented. Major producers in China are profiled. The primary and secondary research is done in China in order to access up-to-date government regulations, market information and industry data. Data were collected from the Chinese government publications, Chinese language newspapers and magazines, industry associations, local governments' industry bureaus, industry publications, and our in-house databases. Interviews are conducted with Chinese industry experts, university professors, and producers in China. Economic models and quantitative methods are applied in this report to project market demand and industry trends. Metric system is used and values are presented in either Yuan (RMB, current price) and/or US dollars. Our market research reports provide hard-to-find market data and analyses. Today, China has the largest market in the world. Tremendous fast-growing markets for imports and business opportunities for companies around the world. If you want to expand your business or sell your products in China, our research reports provide the insights and projections into Chinese markets necessary for you to do so. Key Topics Covered: I. INTRODUCTION Report Scope and Methodology Executive Summary II. BUSINESS ENVIRONMENT Economic Outlook Key Economic Indicators Industrial Output Population and Labor Foreign Investment Foreign Trade Financial and Tax Regulations Banking System and Regulations Foreign Exchange Taxes, Tariff and Custom Duties III. SLEEP DISORDER TREATMENT DRUGS INDUSTRY ASSESSMENTS Sleep Disorder Treatment Drugs Industry Structure Market Size Market Growth Driver Sleep Disorder Treatment Drugs Sales Volume Major Producer Facility Locations and Sales Volume Market Share of Key Producers Labor Cost Potential Entrants Major Distributors Major Foreign Investments Technology Development IV. SLEEP DISORDER TREATMENT DRUGS PRODUCTION AND DEMAND Overview Sales Volume of Sleep Disorder Treatment Drugs by Region Sleep Disorder Treatment Drugs Sales Volume Western Sleep Disorder Treatment Drugs Sales Volume Barbiturates Phenobarbital Secobarbital Amobarbital Benzodiazepines Midazolam Estazolam Triazolam Others Non-benzodiazepines Zolpidem Zopiclone Zaleplon Others Chinese Traditional Sleep Disorder Treatment Drugs Sales Volume Acanthopanacis Senticosi Gastrodin Chinese Patent Medicines Sleep Disorder Treatment Drugs Imports and Exports Pricing Trends V. SLEEP DISORDER TREATMENT DRUGS MARKET OUTLOOK Sleep Disorder Treatment Drugs Markets Outlook Government Regulations Health Care Insurance Industry Overview Consumer Spending Trends Northeast North Southeast Central Southwest Northwest Demographic Trends Health Care Industry Trends Hospitals and Hospital Beds VI. MARKETING STRATEGIES China Market Entry Overview China's Distribution System Sleep Disorder Treatment Drugs Distribution Channels Transportation and Freight Infrastructure Communications China's Market Entry Export to China Indirect export Direct Export License and Contract Manufacture Assembling in China Contract Manufacturing Trade Permit Investment Equity Joint Venture Contractual Joint Venture Wholly Foreign-Owned Enterprise VII. SLEEP DISORDER TREATMENT DRUGS PRODUCER DIRECTORY Sleep Disorder Treatment Drugs Producer Profiles and Directory A selection of companies mentioned in this report includes Wusuli River Pharmaceutical Group Wandashan Pharmaceutical Factory For more information about this report visit https://www.researchandmarkets.com/r/irmoip About ResearchAndMarkets.com ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.